ELECTRONICALLY TRANSMITTED TO THE SECURITIES AND EXCHANGE COMMISSION ON
MAY 12, 2000
REGISTRATION NO. 333-_______
================================================================================
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------
FORM S-3
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
--------------
PROXYMED, INC.
(Exact name of Registrant as specified in its charter)
FLORIDA 65-0202059
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification No.)
JOHN B. OKKERSE, JR., PH.D
CHIEF EXECUTIVE OFFICER
PROXYMED, INC.
2555 DAVIE ROAD, SUITE 110 2555 DAVIE ROAD, SUITE 110
FORT LAUDERDALE, FLORIDA 33317 FORT LAUDERDALE, FLORIDA 33317
(954) 473-1001 (954) 473-1001
(Address, including zip code, and (Name, address, including zip code,
telephone number, including and telephone number, including
area code, of registrant's area code, of agent for service)
principal executive offices)
-----------------
COPIES OF COMMUNICATIONS TO:
FRANK M. PUTHOFF, ESQ. STEVEN SONBERG, ESQ.
EXECUTIVE VICE PRESIDENT AND HOLLAND & KNIGHT LLP
CHIEF LEGAL OFFICER 701 BRICKELL AVENUE
PROXYMED, INC. SUITE 3000
2555 DAVIE ROAD, SUITE 110 MIAMI, FLORIDA 33131
FORT LAUDERDALE, FLORIDA 33317 (305) 374-8500
(954) 473-1001
------------------
APPROXIMATE DATE OF COMMENCEMENT OF PROPOSED SALE TO THE PUBLIC:
From time to time as described in the Prospectus after the effective date
of this Registration Statement.
------------------
If the only securities being registered on this Form are being offered
pursuant to dividend or interest reinvestment plans, please check the following
box. [ ]
If any of the securities being registered on this Form are to be
offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933 (the "Securities Act"), other than securities offered
only in connection with dividend or interest reinvestment plans, check the
following box. [X]
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. [ ]
If this Form is a post-effective amendment filed pursuant to Rule
462(c) under the Securities Act, check the following box and list the Securities
Act registration statement number of the earlier effective registration
statement for the same offering. [ ]
If delivery of the prospectus is expected to be made pursuant to Rule
434, please check the following box. [ ]
------------------
CALCULATION OF REGISTRATION FEE
<TABLE>
<CAPTION>
========================================== ====================== ====================== ====================== ====================
AMOUNT TO PROPOSED MAXIMUM PROPOSED MAXIMUM
TITLE OF EACH CLASS OF BE OFFERING PRICE PER AGGREGATE OFFERING AMOUNT OF
SECURITIES TO BE REGISTERED REGISTERED(1)(2) SHARE(3) PRICE(3) REGISTRATION FEE
- ------------------------------------------ ---------------------- ---------------------- ---------------------- --------------------
<S> <C> <C> <C> <C> <C>
Common Stock ($.001 par value)..... 18,873,590 shares $1.6563 $31,260,328 $8,253
========================================== ====================== ====================== ====================== ====================
</TABLE>
(1) A total of 4,589,043 shares of common stock were previously registered on
Form S-3 (file no. 333-95883), filed with the Securities and Exchange
Commission on February 1, 2000 and declared effective on February 11, 2000.
Of the 4,589,043 shares of common stock previously registered, 531,150
shares have been sold. Due to a recent
<PAGE>
decrease in the market price of the common stock, the Company is required
by the Registration Rights Agreement dated as of December 23, 1999 and a
Registration Rights Agreement dated May 4, 2000 to register an additional
14,284,547 shares of common stock. In accordance with Rule 429 of
Regulation C of the Securities and Exchange Act of 1933, as amended, the
Company is presenting a combined prospectus. The Company previously paid a
filing fee of $10,449.25 with the earlier registration statement and is
paying an additional filing fee of $6,247 with respect to the additional
shares being registered under this registration statement.
(2) For purposes of estimating the number of shares of common stock required to
be included in this Registration Statement, we included (i) 12,994,902
shares, representing 200% of the number of shares of common stock issuable
upon conversion of the Series B Convertible Preferred Stock, determined as
if the Series B Convertible Preferred Stock were converted in full at the
conversion price (as defined) of $1.54 as of May 10, 2000; plus (ii)
1,713,784 shares, representing 200% of the number of shares of common stock
issuable upon exercise of the outstanding warrants issued in connection
with the Series B Convertible Preferred Stock (without regard to any
limitations on exercise) as of May 10, 2000; plus (iii) 50,000 shares of
common stock representing 200% of the number of shares of common stock
issuable upon exercise of the warrant issued to Transamerica Business
Credit Corporation; plus (iv) 1,386,666 shares of common stock representing
200% of the number of shares of common stock issuable upon exercise of the
exchanged warrants issued to certain holders of the Series B Preferred
Stock (without regard to any limitations on exercise) in connection with
the Redemption and Exchange Agreement as of May 4, 2000; plus (v) 1,300,000
shares of common stock representing 200% of the number of shares of common
stock issuable upon exercise of the new warrants issued to certain holders
of the Series B Preferred Stock (without regard to any limitations on
exercise) in connection with the Redemption and Exchange Agreement as of
May 4, 2000; plus (vi) 1,428,238 shares of common stock representing 200%
of the number of shares of common stock issuable as dividends upon the
Series B Preferred Stock.
(3) Estimated solely for the purpose of computing the registration fee pursuant
to Rule 457(c) of the Securities Act of 1933 and based on the closing price
for the common stock on May 10, 2000 as reported by the Nasdaq National
Market.
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE
OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT
SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION
STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(A) OF
THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME
EFFECTIVE ON SUCH DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(A),
MAY DETERMINE.
================================================================================
<PAGE>
The information in this prospectus is not complete and may be changed.
The selling shareholders may not sell the securities offered by this prospectus
until the registration statement filed with the Securities and Exchange
Commission is effective. This prospectus is not an offer to sell these
securities and it is not soliciting an offer to buy these securities in any
state where the offer or sale is not permitted.
SUBJECT TO COMPLETION, DATED MAY 12, 2000
PROSPECTUS
SHARES
[PROXYMED, INC. LOGO]
COMMON STOCK
---------------
This prospectus relates to up to 18,873,590 shares of common stock of
ProxyMed, Inc. which may be sold from time to time by the selling shareholders
listed on page 15, or their transferees, pledgees, donees or successors. The
number of shares of common stock that we actually issue, and thus the number of
shares that may be sold hereunder, may be more or less than the 18,873,590
shares being offered by the selling shareholders through this prospectus,
because the conversion of the Series B Convertible Preferred Stock described in
this prospectus is based upon a formula that is dependent upon the market price
of our common stock and anti-dilution provisions contained in certain warrants.
The shares are being registered to permit the selling shareholders to
sell the shares from time to time in the public market. The selling shareholders
may sell the common stock through ordinary brokerage transactions, directly to
market makers of our shares, or through any other means described in the section
entitled "Plan of Distribution" beginning on page 27. We cannot assure you that
the selling shareholders will sell all or any portion of the common stock
offered hereby.
The selling shareholders are selling these shares for their own
accounts. We will not receive any of the proceeds from the sale of these shares,
although we have paid the expenses of preparing this prospectus and the related
registration statement.
Our common stock is traded on the Nasdaq National Market under the
symbol "PILL."
-------
INVESTING IN OUR COMMON STOCK INVOLVES SIGNIFICANT RISKS. SEE "RISK
FACTORS" BEGINNING ON PAGE 5.
--------
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities, or determined if
this prospectus is truthful or complete. Any representation to the contrary is a
criminal offense.
---------------
THE DATE OF THIS PROSPECTUS IS MAY ___, 2000
<PAGE>
No one (including any salesman or broker) is authorized to provide oral or
written information about this offering that is not included in this prospectus.
TABLE OF CONTENTS
PAGE
WHERE YOU CAN FIND MORE INFORMATION...........................................2
FORWARD-LOOKING INFORMATION...................................................3
ABOUT PROXYMED................................................................3
RISK FACTORS..................................................................5
USE OF PROCEEDS..............................................................13
SELLING SHAREHOLDERS.........................................................15
DESCRIPTION OF SECURITIES....................................................19
PLAN OF DISTRIBUTION.........................................................27
LEGAL OPINION................................................................28
EXPERTS......................................................................28
WHERE YOU CAN FIND MORE INFORMATION
We file annual, quarterly and special reports, proxy statements and
other information with the SEC. You may read and copy any document we file at
the public reference facilities of the SEC in Washington, D.C., Chicago,
Illinois and New York, New York. Please call the SEC at 1-800-SEC-0330 for
further information on the public reference rooms. Our SEC filings are also
available to the public from the SEC's web site at http://www.sec.gov.
The SEC allows us to "incorporate by reference" the information we have
filed with it, which means that we can disclose important information to you by
referring you to those documents. The information incorporated by reference is
considered to be part of this prospectus, and information that we file later
with the SEC will automatically update and supersede this information. We
incorporate by reference into this prospectus the following documents listed
below and any future filings that we make with the SEC under Sections 13(a),
13(c), 14 or 15(d) of the Securities Exchange Act of 1934:
(1) Our Annual Report on Form 10-K for the year ended December 31,
1999;
(2) Our Current Report on Form 8-K dated December 23, 1999 (relating
to the private placement of the Series B Convertible Preferred
Stock);
(3) Our Current Report on Form 8-K dated May 8, 2000;
(4) Our Current Report on Form 8-K dated May 9, 2000; and
(5) Our preliminary Proxy Statement, dated May 10, 2000, filed in
connection with our 1999 Annual Meeting of Shareholders.
You may request a copy of these filings, at no cost, by writing or
telephoning us at the following address:
ProxyMed, Inc.
2555 Davie Road, Suite 110
Fort Lauderdale, Florida 33317
Attn: Investor Relations
Telephone: (954) 473-1001, ext. 300
2
<PAGE>
FORWARD-LOOKING INFORMATION
This prospectus, including the information incorporated by reference,
contains forward-looking statements made pursuant to the safe harbor provisions
of the Private Securities Litigation Reform Act of 1995. Actual results could
differ materially from those projected in the forward-looking statements as a
result of the risk factors beginning on page 6 and others, certain of which may
be detailed from time to time in our periodic reports filed with the SEC.
ABOUT PROXYMED
ProxyMed, Inc. is an e-commerce healthcare information services company
primarily engaged in healthcare electronic transaction processing services and
communication devices. We provide healthcare electronic transaction processing
services and related software products to physicians, independent physician
associations, insurance companies, managed care organizations, pharmacies,
commercial and hospital laboratories and nursing homes. Our electronic
transaction processing services support a broad range of both financial and
clinical transactions. To facilitate these services, we have developed and
operate ProxyNet,(R) our proprietary national electronic healthcare information
network, which provides physicians and other primary care providers with direct
connectivity to one of the industry's largest lists of payers, the largest list
of chain and independent pharmacies and the largest list of clinical
laboratories.
The healthcare industry generates billions of financial and clinical
transactions each year, including prescription orders, refill authorizations,
lab orders and results, radiology orders and results, medical insurance claims,
insurance eligibility inquiries, encounter notifications, and referral requests
and authorizations. We believe that the healthcare industry lags behind many
other transaction-intensive industries, such as the travel, securities and
banking industries, in the number of transactions processed electronically, with
the vast majority of healthcare transactions being performed manually and on
paper. For physicians, payers, labs and pharmacies to meet the financial and
clinical demands of an evolving managed care system, we believe that
participants in the healthcare system will need to process many of these types
of transactions electronically. Due to the number of participants, lack of
standards and complexity of establishing reliable and secure communication
networks, the healthcare industry needs companies such as ProxyMed, with its
secure, proprietary systems, to facilitate the processing of these transactions.
Physicians control most healthcare decisions and are a central point
for patient-related financial and clinical transactions generated each year.
Because of our broad range of both financial and clinical transaction
capabilities, we are positioned to provide "one-stop shopping" for all of a
physician's electronic transaction processing needs. ProxyMed's goal is to
become the nation's leading provider of physician office connectivity and
transaction processing services.
To gain access to the greatest number of physicians, we utilize the
following sales and distribution channels for our healthcare electronic
transaction processing and communication devices business:
Distribution Channel Focus
- -------------------- -----
ProxyMed Software ProxyMed has a direct sales force that
and Communication serves physicians, payers, pharmacies and
Devices - Direct Sales labs. ProxyMed licenses its proprietary
software products for use on physician
desktops for access to ProxyNet,
transaction creation and communication
between healthcare participants.
Electronic Commerce Partners ProxyMed has established its electronic
commerce partner program to work with the
nation's leading providers of physician
desktop
3
<PAGE>
software, so that they may enable their
existing applications to communicate
through ProxyNet to payers, pharmacies and
labs.
Gateway Agreements ProxyMed connects other electronic
transaction processing networks to
ProxyNet so that the participants on both
networks can communicate with each other.
proxyMed.com ProxyMed is establishing itself as a
provider of financial and clinical
electronic transaction processing services
through the world wide web, which may be
accessed by any physician with an internet
connection.
Physicians, which we describe as "front-end" customers, pay recurring
network access and database subscription fees, as well as software license,
purchase and service fees for our desktop equipment, software and communication
devices. Payers, laboratories and pharmacies, which we describe as "back-end"
customers, pay for transaction processing services on a per transaction basis.
SALE OF NETWORK ENGINEERING SERVICES AND DRUG DISPENSING DIVISIONS
On March 31, 2000, we completed the sale of our network integration
division and our prescription drug dispensing subsidiary, ProxyCare, Inc., in
separate transactions valued at approximately $3.7 million.
* * *
Our principal executive offices are located at 2555 Davie Road, Suite
110, Fort Lauderdale, Florida 33317-7424, and our telephone number is (954)
473-1001.
RECENT FINANCIAL INFORMATION
On April 19, 2000, we announced in a press release our unaudited
financial results as of and for the three month period ended March 31, 2000,
which is summarized below:
Revenues $ 7,644,950
Net loss from continuing operations $(5,929,295)
Net loss applicable to common shareholders $(5,948,763)
Basic and diluted net loss per common share $ (.32)
Total shareholders' equity $30,562,604
4
<PAGE>
RISK FACTORS
In addition to the other information in this prospectus or incorporated
in this prospectus by reference, you should consider carefully the following
factors in evaluating ProxyMed and our business before purchasing the common
stock offered by this prospectus.
RISKS RELATED TO OUR BUSINESS
WE HAVE INCURRED LOSSES IN THE PAST AND WE EXPECT LOSSES IN THE FUTURE WHICH
COULD HAVE A DETRIMENTAL EFFECT ON THE MARKET PRICE OF OUR STOCK
We have incurred substantial losses, including a loss of $5,722,000 for
the three months ended March 31, 2000, and losses of $21,856,000, $11,788,000
and $18,517,000 for the fiscal years ended December 31, 1999, 1998 and 1997,
respectively. As of March 31, 2000, we had an accumulated deficit of
$69,462,000. We expect to continue to incur substantial losses for the
foreseeable future, including a substantial charge in the second quarter 2000
relating to the Series B Preferred Stock discussed below. We can give no
assurance that we will ever achieve profitable operations. This could have a
detrimental effect on the market price of our stock.
WE DEPEND ON CONNECTIONS TO INSURANCE COMPANIES AND OTHER PAYERS, AND IF WE LOSE
THESE CONNECTIONS, OUR SERVICE OFFERINGS WOULD BE LIMITED AND LESS DESIRABLE TO
HEALTHCARE PARTICIPANTS
Our business is enhanced by the substantial number of payers, such as
insurance companies, Medicare and Medicaid agencies, laboratories and
pharmacies, to which we have electronic connections. These connections may
either be made directly or through a clearinghouse. We have attempted to enter
into suitable contractual relationships to ensure long-term payer connectivity;
however, we cannot assure that we will be able to maintain our links with all
these payers. In addition, we cannot assure that we will be able to develop new
connections, either directly or through clearinghouses, on satisfactory terms.
Lastly, some third-party payers provide systems directly to healthcare
providers, bypassing us and other third-party processors. Our failure to
maintain existing connections with payers and clearinghouses or to develop new
connections as circumstances warrant, or an increase in the utilization of
direct links between providers and payers, could cause our electronic
transaction processing system to be less desirable to healthcare participants,
which would slow down or reduce the number of transactions that we process and
for which we are paid.
EVOLVING INDUSTRY STANDARDS AND RAPID TECHNOLOGICAL CHANGES COULD RESULT IN OUR
PRODUCTS BECOMING OBSOLETE OR NO LONGER IN DEMAND
Rapidly changing technology, evolving industry standards and the
frequent introduction of new and enhanced internet-based services characterize
the market for our products and services. Our success will depend upon our
ability to enhance our existing services, introduce new products and services on
a timely and cost-effective basis to meet evolving customer requirements,
achieve market acceptance for new products or services and respond to emerging
industry standards and other technological changes. We cannot assure that we
will be able to respond effectively to technological changes or new industry
standards. Moreover, we cannot assure that other companies will not develop
competitive products or services, or that any such competitive products or
services will not cause our products and services to become obsolete or no
longer in demand.
THE ACCEPTANCE OF ELECTRONIC TRANSACTION PROCESSING IN THE HEALTHCARE INDUSTRY
IS STILL IN ITS EARLY STAGES; THUS, THE FUTURE OF OUR BUSINESS, INCLUDING OUR
NEW INTERNET-BASED APPLICATIONS, IS UNCERTAIN
Our strategy anticipates that electronic processing of healthcare
transactions, including transactions involving clinical as well as financial
information, will become more widespread and
5
<PAGE>
that providers and third-party payers increasingly will use electronic
transaction processing networks for the processing and transmission of data.
Electronic transmission of healthcare transactions (and, in particular, the use
of the internet to transmit them) is still developing, and complexities in the
nature and types of transactions which must be processed have hindered, to some
degree, the development and acceptance of electronic transaction processing in
this industry. We cannot assure that continued conversion from paper-based
transaction processing to electronic transaction processing in the healthcare
industry, using proprietary physician management systems or the internet, will
occur. The internet may prove not to be a viable commercial marketplace for a
number of reasons, including:
o inadequate development of the necessary infrastructure for
communication speed, access and server reliability,
o security and confidentiality concerns,
o lack of development of complementary products, such as high-speed
modems and high-speed communication lines,
o implementation of competing technologies,
o delays in the development or adoption of new standards and
protocols required to handle increased levels of internet
activity, and
o possible governmental regulation.
Growth in the demand for our new internet applications and services
depends on the adoption of internet solutions by healthcare participants, which
requires the acceptance of a new way of conducting business and exchanging
information. The healthcare industry, in particular, relies on legacy systems
that may be unable to benefit from our new internet-based platform. Customers
using legacy and client-server systems may refuse to adopt our new
internet-based systems when they have made a substantial investment in hardware,
software and training for older systems.
IF ELECTRONIC TRANSACTION PROCESSING PENETRATES THE HEALTHCARE INDUSTRY, WE MAY
FACE PRESSURE TO REDUCE OUR PRICES WHICH POTENTIALLY MAY LEAD TO FURTHER LOSSES
If electronic transaction processing extensively penetrates the
healthcare market or becomes highly standardized, it is possible that
competition among electronic transaction processors will focus increasingly on
pricing. This competition may put intense pressure on us to reduce our pricing
in order to retain market share. If we are unable to reduce our costs
sufficiently to offset declines in our prices, or if we are unable to introduce
new, innovative service offerings with higher prices, we will continue to incur
net losses.
PROPOSED HEALTHCARE LEGISLATION AND CHANGES TO EXISTING LAWS COULD CAUSE AN
EROSION OF OUR CURRENT COMPETITIVE STRENGTHS
Our customers are subject to extensive and frequently changing federal
and state healthcare laws and regulations. Political, economic and regulatory
influences are subjecting the healthcare industry in the United States to
fundamental change. Potential reform legislation may include:
o mandated basic healthcare benefits,
6
<PAGE>
o controls on healthcare spending through limitations on the growth
of private health insurance premiums and Medicare and Medicaid
reimbursement,
o the creation of large insurance purchasing groups, and
o fundamental changes to the healthcare delivery system.
The federal Health Insurance Portability and Accountability Act of
1996, known as HIPAA for short, mandates the use of standard transactions,
standard identifiers, security and other provisions for electronic claims
transactions. HIPAA specifically designates clearinghouses (including us and
other financial network operators) as the compliance facilitators for healthcare
providers and payers. Clearinghouses are given the freedom to utilize
non-standard transactions and convert them to the mandated standards on behalf
of their customers. We intend to comply with the mandated standards as soon as
practicable after they have been adopted. Due to mandated standards, however,
there is a possibility that it will be easier for competitors to offer
electronic transaction processing services similar to ours, which would make our
competitive strength of accepting financial transactions in multiple formats
less of a differentiating factor for our customers.
We anticipate Congress and some state legislatures will continue to
review and assess alternative healthcare delivery systems and payment methods
and public debate of these issues will likely continue in the future. Due to
uncertainties as to these reform initiatives and their enactment and
implementation, we cannot predict which, if any, of such reform proposals will
be adopted, when they may be adopted or what impact they may have on us.
BECAUSE WE ARE SMALLER AND HAVE FEWER FINANCIAL RESOURCES THAN MANY OF OUR
COMPETITORS, WE MAY NOT BE ABLE TO SUCCESSFULLY COMPETE IN THE VERY COMPETITIVE
HEALTHCARE ELECTRONIC TRANSACTION PROCESSING INDUSTRY
We face competition from many healthcare information systems companies
and other technology companies. Many of our competitors are significantly larger
and have greater financial resources than we do and have established reputations
for success in implementing healthcare electronic transaction processing
systems. Other companies have targeted this industry for growth, including the
development of new technologies utilizing internet-based systems. We cannot
assure that we will be able to compete successfully with these companies or that
these or other competitors will not commercialize products, services or
technologies that render our products, services or technologies obsolete or less
marketable.
We also believe that most physicians will ultimately subscribe to only
one electronic transaction processing service provider. Consequently, it is our
belief that the key to competitive success will be our ability to control
physicians' desktops by offering a comprehensive set of electronic financial and
clinical transactions and locking in the physicians to mutually beneficial
long-term agreements. However, we cannot assure that we will win this race to
provide "one-stop shopping," or that this belief about physicians' preference
for "one-stop shopping" will prove correct. Due to advances in technology,
changes in attitudes and other factors, physicians may ultimately prefer to use
multiple electronic transaction processing services and may elect to change
their electronic transaction processing services frequently rather than settling
long-term for one provider.
7
<PAGE>
WE HAVE IMPORTANT BUSINESS RELATIONSHIPS WITH OTHER COMPANIES TO MARKET AND SELL
SOME OF OUR CLINICAL PRODUCTS AND SERVICES WHICH HAVE NOT RESULTED IN
SIGNIFICANT SALES YET AND IF THESE COMPANIES ARE UNSUCCESSFUL, WE WILL NEED TO
ADD THIS EMPHASIS INTERNALLY, WHICH MAY DIVERT OUR EFFORTS AND RESOURCES FROM
OTHER PROJECTS
For the marketing and sale of some of our clinical products and
services, we entered into important business relationships with other companies,
through our electronic commerce partner program with physician office management
information system vendors and electronic medical record vendors and through
other agreements. These important business relationships, which have required
and will continue to require significant commitments of effort and resources,
have yet to generate substantial recurring revenue, and we cannot assure that
they will ever generate substantial recurring revenue. Most of these
relationships are on a non-exclusive basis, and we cannot assure that our
electronic commerce partners and other strategic partners, most of whom have
significantly greater financial and marketing resources than we do, will not
develop and market products and services in competition with us in the future or
will not otherwise discontinue their relationship with us. Also, our
arrangements with some of our partners involve negotiated payments to the
partners based on percentages of revenues generated by the partners. If the
payments prove to be too high, we may be unable to realize acceptable margins,
but if the payments prove to be too low, the partners may not be motivated to
produce a sufficient volume of revenues. The success of our important business
relationships will depend in part upon our partners' own competitive, marketing
and strategic considerations, including the relative advantages of alternative
products being developed and marketed by such partners. If any such partners are
unsuccessful in marketing our products, we will need to place added emphasis on
these aspects of our business internally, which may divert our planned efforts
and resources from other projects.
OUR CLINICAL TRANSACTION PRODUCTS AND SERVICES HAVE YET TO BE TESTED ON A LARGE
SCALE AND COULD FAIL UNDER A HEAVY CUSTOMER LOAD
The quality of our clinical transaction products and services is
important to our business. Although we have completed the development of most of
our clinical transaction products and services and our electronic transaction
processing network, which we believe efficiently perform the principal functions
for which they have been designed, our clinical transaction products and
services and the network are currently being utilized only by a limited number
of customers for these transactions. We cannot assure that, upon widespread
commercial use of our clinical transaction products and services, they will
satisfactorily perform all of the functions for which we have designed them or
that unanticipated technical or other errors will not occur which would result
in increased costs or material delays. Any of these errors could delay our
plans, result in harmful publicity or cause us to incur substantial remedial
costs.
COMPUTER NETWORK SYSTEMS LIKE OURS COULD SUFFER SECURITY AND PRIVACY BREACHES
THAT COULD HARM OUR CUSTOMERS AND US
We currently operate servers and maintain connectivity from multiple
facilities. Despite our implementation of network security measures, such as
limiting physical and network access to routers, our infrastructure may be
vulnerable to computer viruses, break-ins and similar disruptive problems caused
by customers or other users. Computer viruses, break-ins or other security
problems could lead to interruption, delays or cessation in service to our
customers. These problems could also potentially jeopardize the security of
confidential information stored in the computer systems of our customers, which
may deter potential customers from doing business with us and give rise to
possible liability to users whose security or privacy has been infringed. The
security and privacy concerns of existing and potential customers may inhibit
the growth of the healthcare information services industry in general, and our
customer base and business in particular. A
8
<PAGE>
significant security breach could result in loss of customers, damage to our
reputation, direct damages, costs of repair and detection and other unplanned
expenses.
WE DEPEND ON UNINTERRUPTED COMPUTER ACCESS FOR OUR CUSTOMERS; ANY PROLONGED
INTERRUPTIONS IN OUR OPERATIONS COULD CAUSE OUR CUSTOMERS TO SEEK ALTERNATIVE
PROVIDERS OF OUR SERVICES
Our success is dependent on our ability to deliver high-quality,
uninterrupted computer networking and hosting, requiring us to protect our
computer equipment and the information stored in servers against damage by fire,
natural disaster, power loss, telecommunications failures, unauthorized
intrusion and other catastrophic events. Although we plan to develop back-up
site capability and have a program to manage technology to reduce risks in the
event of a disaster, including periodic "back-ups" of our computer programs and
data, any damage or failure resulting in prolonged interruptions in our
operations could cause our customers to seek alternative providers of our
services. In particular, a system failure, if prolonged, could result in reduced
revenues, loss of customers and damage to our reputation, any of which could
cause our business to suffer. While we carry property and business interruption
insurance to cover operations, the coverage may not be adequate to compensate us
for losses that may occur.
OUR PRODUCTS EMPLOY PROPRIETARY INFORMATION AND TECHNOLOGY WHICH MAY INFRINGE ON
THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES
In large part, our success is dependent on our proprietary information
and technology. We rely on a combination of contract, copyright, trademark and
trade secret laws and other measures to protect our proprietary information and
technology. We have federal trademark registrations for ClinScan, PreScribe,
ProxyNet, ProxyScript and RxReceive and have filed a trademark application for
"empowering physicians with eSolutions," which is currently pending approval. We
have no patents. We have copyright registrations for twelve of our software
products. As part of our confidentiality procedures, we generally enter into
nondisclosure agreements with our employees, distributors and customers, and
limit access to and distribution of our software, databases, documentation and
other proprietary information. We cannot assure that the steps taken by us will
be adequate to deter misappropriation of our proprietary rights or that third
parties will not independently develop substantially similar products, services
and technology. Although we believe our products, services and technology do not
infringe on any proprietary rights of others, as the number of software products
available in the market increases and the functions of those products further
overlap, we and other software and internet developers may become increasingly
subject to infringement claims. These claims, with or without merit, could
result in costly litigation or might require us to enter into royalty or
licensing agreements, which may not be available on terms acceptable to us.
BECAUSE AN ERROR BY ANY PARTY IN THE PROCESS OF PRESCRIBING DRUGS AND FILLING
PRESCRIPTIONS COULD RESULT IN SUBSTANTIAL INJURY TO A PATIENT, OUR LIABILITY
INSURANCE MAY NOT BE ADEQUATE IN A CATASTROPHIC SITUATION
Our business exposes us to potential liability risks that are
unavoidably part of being in the healthcare electronic transaction processing
industry. Many of our products and services relate to prescribing drugs and
filling prescriptions, and an error by any party in the process could result in
substantial injury to a patient. As a result, our liability risks are
significant. We cannot assure that our insurance will be sufficient to cover
potential claims arising out of our current or proposed operations, or that our
present level of coverage will be available in the future at a reasonable cost.
A partially or completely uninsured claim against us, if successful and of
sufficient magnitude, would have significant adverse financial consequences. Our
inability to obtain insurance of the type and in the amounts we require could
generally impair our ability to market our products and services.
9
<PAGE>
WE MAY NOT BE ABLE TO RETAIN KEY PERSONNEL OR REPLACE THEM IF THEY LEAVE
Our success is largely dependent on the personal efforts of Harold S.
Blue, our Chairman, John B. Okkerse, Jr., Ph.D., our Chief Executive Officer,
and John Paul Guinan, President of our internet division. Although we have
entered into employment agreements with these and a few other senior executives,
the loss of any of their services could cause our business to suffer. We have
obtained for our benefit "key person" insurance on the lives of Messrs. Blue and
Guinan in the amount of $1,000,000. Our success is also dependent upon our
ability to hire and retain qualified marketing, operations, development and
other personnel. Competition for qualified personnel in the healthcare
information services industry is intense, and we cannot assure that we will be
able to hire or retain the personnel necessary for our planned operations.
BELLINGHAM OWNS A SUBSTANTIAL AMOUNT OF OUR STOCK AND IS CAPABLE OF INFLUENCING
OUR AFFAIRS AND STOCK PRICE
As of the date of this prospectus, Bellingham Industries Inc., an
offshore investment fund, beneficially owns approximately 9% of our outstanding
common stock, down from 32.1% as of March 10, 2000. A significant number of
shares of our common stock owned by Bellingham have been sold by brokerage firms
as a result of margin calls. We have been advised that Bellingham continues to
be subject to possible margin calls and cannot determine when margin sales on
behalf of Bellingham will be discontinued. Continued margin selling of
Bellingham's shares may have an adverse effect on our stock price.
OUR CORPORATE CHARTER CONTAINS AUTHORIZED, UNISSUED PREFERRED STOCK WHICH, IF
ISSUED, MAY INHIBIT A TAKEOVER AT A PREMIUM PRICE THAT MAY BE BENEFICIAL TO OUR
SHAREHOLDERS
Our Articles of Incorporation authorize the issuance of 2,000,000
shares of "blank check" preferred stock with such designations, rights and
preferences as our Board of Directors may determine from time to time. Of these
preferred shares, 1,990,690 shares are outstanding as of the date of this
prospectus. Without shareholder approval, our Board of Directors is empowered to
issue shares of our preferred stock with dividend, liquidation, conversion,
voting and other rights that could lessen the value, voting power or other
rights of holders of common stock. Issuance of shares of our preferred stock
could be utilized, under some circumstances, as a method of discouraging,
delaying or preventing a change of control of this company at a premium price
which would be beneficial to our shareholders.
INVESTORS SHOULD NOT ANTICIPATE RECEIVING CASH DIVIDENDS ON OUR COMMON STOCK
We currently anticipate retaining all of our future earnings, if any,
for use in the operation and expansion of our business, and do not plan to pay
any cash dividends on shares of our common stock in the foreseeable future. The
provisions of the Series B Preferred Stock prohibit the payment of dividends on
our common stock unless we get the consent of the holders of two-thirds of the
Series B Preferred Stock. Potential investors who anticipate a need for
dividends should not invest in this stock.
OUR COMMON STOCK PRICE HAS FLUCTUATED CONSIDERABLY AND MAY NOT APPRECIATE IN
VALUE
The market price of shares of our common stock has fluctuated
substantially in recent years and is likely to fluctuate significantly from its
current level. In 1998, for example, the closing market price of our shares
ranged from a low of $5.25 per share to a high of $17.13 per share, and during
1999, our closing share price has ranged from a low of $9.50 per share to a high
of $19.25 per share. Through May 10, 2000, our closing share price has ranged
from a high of $11.30 per share to a low of $1.25 per share. Future
announcements concerning our financial performance, conversion of
10
<PAGE>
shares of the Series B Preferred Stock, margin calls, the introduction of new
products, services or technologies or changes in product pricing policies by us
or our competitors or changes in earnings estimates by analysts, among other
factors, could cause the market price of our common stock to fluctuate
substantially. Stock markets have experienced extreme price and volume
volatility in the last year. This volatility has had a substantial effect on the
market prices of securities of many public companies for reasons frequently
unrelated to the operating performance of the specific companies. These broad
market fluctuations may also cause declines in the market price of our common
stock. Investors seeking short-term liquidity should be aware that we cannot
assure that the stock price will appreciate in value or, as noted above, that
cash dividends will be paid.
RISKS RELATED TO THE SERIES B CONVERTIBLE PREFERRED STOCK
THE CONVERSION OF THE SERIES B PREFERRED STOCK AND THE EXERCISE OF THE RELATED
WARRANTS COULD RESULT IN A SUBSTANTIAL NUMBER OF ADDITIONAL SHARES BEING ISSUED
IF THE MARKET PRICE OF OUR COMMON STOCK DECLINES
The Series B Preferred Stock converts into common stock at a floating
rate based on the market price of our common stock, provided the conversion
price may not exceed $21.26. As a result, the lower the price of our common
stock at the time the holder converts, the greater the number of shares of
common stock the holder will receive.
To the extent the Series B Preferred Stock is converted or dividends on
the Series B Preferred Stock are paid in shares of common stock rather than
cash, a significant number of additional shares of common stock may be sold into
the market, which could decrease the price of our common stock due to the
additional supply of shares relative to demand in the market. In that case, we
could be required to issue an increasingly greater number of shares of our
common stock upon future conversions of the Series B Preferred Stock, sales of
which could further depress the price of our common stock.
If the sale of a large amount of shares of our common stock upon
conversion of, or the payment of dividends in lieu of cash on, the Series B
Preferred Stock results in a decline in the price of our common stock, this
event could encourage short sales of our common stock or margin calls upon
investors in our common stock. Short sales or margin calls could place further
downward pressure on the price of our common stock.
The conversion of, and the payment of dividends in shares of common
stock in lieu of cash on, the Series B Preferred Stock may result in substantial
dilution to the interests of other holders of our common stock. Even though no
selling shareholder may convert its Series B Preferred Stock into more than
4.99% of our then outstanding common stock (excluding for purposes of such
determination shares of common stock issuable upon conversion of Series B
Preferred Stock which have not been converted and upon exercise of warrants
which have not been exercised), this restriction does not prevent a selling
shareholder from selling a substantial number of shares in the market. By
periodically selling shares into the market, an individual selling shareholder
could eventually sell more than 4.99% of our outstanding common stock while
never holding more than 4.99% at any specific time.
At a conversion price of $1.54, the outstanding shares of Series B
Preferred Stock on May 10, 2000, would be convertible into approximately
6,044,046 shares, representing approximately 23.4% of the common stock that
would be outstanding following the conversion, based upon the common shares
outstanding on May 10, 2000. As of May 10, 2000, 1,690 shares of Series B
Preferred Stock had been converted into 1,401,516 shares of our common stock.
11
<PAGE>
OUR INABILITY TO COMPLY WITH THE TERMS OF THE REDEMPTION AND EXCHANGE AGREEMENT
COULD RESULT IN OUR INABILITY TO REDEEM TO THE SERIES B PREFERRED STOCK AND
COULD RESULT IN A SUBSTANTIAL NUMBER OF ADDITIONAL SHARES BEING ISSUED
Effective May 4, 2000, we entered into a Redemption and Exchange
Agreement (the "Redemption Agreement") with holders of 13,000 shares of the
Series B Preferred Stock. Under the terms of the Redemption Agreement, we
redeemed 4,000 shares of the Series B Preferred Stock, and are required to
redeem an additional 2,500 shares of the Series B Preferred Stock on each of
June 19, 2000, August 1, 2000, and August 31, 2000, and an additional 1,500
shares of the Series B Preferred Stock on September 29, 2000. The Redemption
Agreement also provides that 693,333 of the original warrants (the "Old
Warrants") issued to the holders of the Series B Preferred Stock subject to the
Redemption Agreement are being exchanged for warrants (the "Exchanged Warrants")
with an exercise price of $1.50 per share and such holders are receiving, in the
aggregate, 650,000 additional warrants (the "New Warrants") at an exercise price
of $1.50 per share. The exercise price and number of shares of common stock
which may be purchased upon exercise of the Exchanged Warrants and the New
Warrants are subject to adjustment upon the occurrence of certain dilution
events including, without limitation, certain issuances of common stock, stock
options or convertible securities or certain corporate transactions such as
stock splits, mergers or asset sales. The redemption of the Series B Preferred
Stock in accordance with the Redemption Agreement is subject to certain closing
conditions on each date of redemption. So long as we remain in compliance with
the terms of the Redemption Agreement, such holders are prohibited from
converting their shares of Series B Preferred Stock into shares of common stock.
Our failure to comply with the terms of the Redemption Agreement would again
allow the holders of the Series B Preferred Stock to convert their shares of
Series B Preferred Stock into shares of common stock. As set forth above, this
could result in the issuance of a substantial number of additional shares of
common stock being issued. In addition, as a result of this restructuring of the
Series B Preferred Stock, we expect to incur a substantial charge in the second
quarter of 2000.
WE WILL BE REQUIRED TO OBTAIN ADDITIONAL FINANCING IN ORDER TO COMPLY WITH THE
REDEMPTION AGREEMENT AND CONTINUE TO FUND OUR CURRENT OPERATIONS
In order for us to comply with the terms of the Redemption Agreement
and continue to fund our operations, we will be required to raise significant
amounts of additional capital. The Redemption Agreement provides that we must
raise at least $4,000,000 of additional funds by June 17, 2000, an additional
$5,000,000 of new funds by July 31, 2000, and an additional $4,000,000 of new
funds by August 30, 2000. We may, however, need or elect to raise additional
funds in excess of such amounts prior to or after such dates. Our capital
requirements will depend on many factors, including our ability to meet the
conditions under the Redemption Agreement, the problems, delays, expenses and
complications frequently encountered by other eHealth companies; the costs
associated with developing improved products and services in response to
technological changes; the costs associated with any marketing or other
arrangements; changes in economic, regulatory, or competitive conditions or our
business; and the cost of retaining management personnel.
To satisfy our capital requirements, we must seek to raise funds
through the issuance of equity or debt in the public or private capital markets.
Our ability to raise additional funds may be adversely affected if, among other
things, we are unable to meet the terms and conditions set forth in the
Redemption Agreement or if we do not continue to improve our operating
performance and achieve increased market acceptance of our products and
services. There can be no assurance that any additional funding will be
available to us, or if available, that it will be available on acceptable terms.
If adequate funds are not available, we will not be able to meet the conditions
set forth in the Redemption Agreement and the holders of the Series B Preferred
Stock would be entitled to exercise their conversion and other rights under the
terms of the designations for the Series B Preferred Stock and the Redemption
Agreement. If we are successful in obtaining additional financing, the
12
<PAGE>
terms of the financing may have the effect of significantly diluting or
adversely affecting the holdings or the rights of the holders of common stock.
WE MAY ISSUE ADDITIONAL SHARES WHICH WOULD REDUCE YOUR OWNERSHIP PERCENTAGE AND
DILUTE THE VALUE OF YOUR SHARES
Certain events over which you have no control could result in the
issuance of additional shares of our common stock, which would dilute your
ownership percentage in ProxyMed. We may issue additional shares of common stock
or preferred stock:
o to raise additional capital or finance acquisitions;
o upon the exercise or conversion of outstanding options, warrants
and shares of convertible preferred stock; or
o in lieu of cash payment of dividends.
As of May 10, 2000, there were outstanding warrants (including the
warrants relating to the Series B Preferred Stock) and options to acquire up to
approximately 6,800,206 additional shares of common stock at prices ranging from
$1.50 to $14.50 per share. If converted or exercised, these securities will
reduce your percentage ownership of common stock and could dilute the value of
your shares. In addition, as disclosed in the preceding risk factor, the number
of shares that may be issued upon conversion of, or payment of dividends in lieu
of cash on, the Series B Preferred Stock could increase substantially if the
market price of our common stock decreases during the period the Series B
Preferred Stock is outstanding.
For example, the number of shares that we would be required to issue
upon conversion of all 9,310 shares of Series B Preferred Stock as of May 10,
2000 would increase from 6,044,046 shares, based on the applicable conversion
price of $1.54 per share as of May 10, 2000, to:
o 8,058,727 shares if the applicable conversion price decreased 25%;
o 12,088,091 shares if the applicable conversion price decreased
50%; or
o 24,176,182 shares if the applicable conversion price decreased
75%.
WE MAY BE REQUIRED TO DELIST OUR SHARES FROM NASDAQ IF CERTAIN EVENTS OCCUR
In accordance with Rule 4460 of the Nasdaq Stock Market Marketplace
Rules, which generally requires shareholder approval of transactions that would
result in the issuance of securities representing 20% or more of an issuer's
outstanding listed securities, we are not obligated to issue shares of common
stock upon conversion or the payment of dividends on the Series B Preferred
Stock in excess of 3,663,730 shares, representing 19.9% of our outstanding
shares of common stock on December 23, 1999, the date of issuance of the Series
B Preferred Stock.
The terms of the Series B Preferred Stock provide that we must obtain
shareholder approval of the issuance of (i) the Series B Preferred Stock, (ii)
the Old Warrants, (iii) common stock issuable upon conversion or exercise
thereof, and (iv) common stock as dividends thereon, by the earlier to occur of
our next annual meeting of shareholders or within 60 days after the date that
the number of shares of common stock then issuable upon conversion of the Series
B Preferred Stock equals or exceeds 2,747,461 shares (15% of the number of
shares of common stock outstanding on the date of issuance of the Series B
Preferred Stock for any three of five consecutive days). On April 13, 2000, we
received a notice from counsel to the holders of the Series B Preferred Stock,
pursuant to Section
13
<PAGE>
4(g) of the Securities Purchase Agreement between the buyers of the Series B
Preferred Stock and ProxyMed dated as of December 23, 1999 (the "Securities
Purchase Agreement"), that for the three days ending on and including April 12,
2000, the number of shares of common stock issuable upon conversion of all the
outstanding shares of Series B Preferred Stock, based upon the Conversion Price
(as defined in the Articles of Amendment) on the applicable date (without regard
to any limitation upon the conversion of the shares of Series B Preferred Stock)
equaled or exceeded 2,747,461 shares, requiring us to hold a shareholders
meeting on or before June 11, 2000. We will not hold a shareholders meeting, and
consequently will not obtain the required shareholder approval, on or before
June 11, 2000.
As a result of not obtaining the required Shareholder Approval of the
Series B Preferred Stock on or prior to June 11, 2000, if we receive a notice
from a holder of Series B Preferred Stock which would require us to convert such
holder's Series B Preferred Stock into a number of shares of common stock which,
when added to all previous shares of common stock issued pursuant to the
conversion of Series B Preferred Stock, would equal or exceed 20% of the number
of shares of common stock outstanding at that time, then we will be required to
either redeem all of the Series B Preferred Stock submitted for redemption or
voluntarily delist our shares from Nasdaq within five business days after the
notice of conversion referred to above. In addition, failure to obtain such
shareholder approval by June 11, 2000, or delisting of the common stock from
Nasdaq, would constitute a "Liquidity Default". See "Effects of Certain Breaches
or Default" under the "Description of Securities." We may not have sufficient
available cash to redeem the Series B Preferred Stock at that time, and thus may
be forced to pursue the option of delisting. In that event, trading in the
common stock would likely decrease substantially, and the price of the common
stock may decline. If we fail to obtain such shareholder approval, there is no
limit on the number of shares of common stock that could be issued upon
conversion of, or the payment of dividends in lieu of cash on, the Series B
Preferred Stock. Notwithstanding the failure to hold a shareholders meeting on
or before June 11, 2000, pursuant to the Redemption Agreement, holders of 13,000
shares of the Series B Preferred Stock have agreed that they will not convert
any of their 9,000 remaining shares of Series B Preferred Stock into common
stock as a result of such failure to hold a meeting if we received such
shareholder approval on or before July 17, 2000, and the remaining holders of
Series B Preferred Stock own only 310 shares of Series B Preferred Stock as of
May 10, 2000.
USE OF PROCEEDS
We will not receive any proceeds from the sale of shares of common
stock by any of the selling shareholders.
We will receive proceeds of $3,590,838 if all of the warrants relating
to the Series B Preferred Stock (including the warrants issued to Transamerica
Business Credit Corporation, the Exchanged Warrants and the New Warrants) are
exercised for cash. We intend to use any proceeds received from the exercise of
warrants for general working capital purposes.
We estimate that our expenses in connection with the filing of this
registration statement will be approximately $30,000.
14
<PAGE>
SELLING SHAREHOLDERS
GENERAL
The shares of common stock being offered by the selling shareholders
are issuable (1) upon conversion of the Series B Preferred Stock, (2) as
dividends on the Series B Preferred Stock, or (3) upon exercise of warrants. For
additional information about the Series B Preferred Stock, see "Description of
Securities - Series B Preferred Stock." We are registering the shares in order
to permit the selling shareholders to offer these shares for resale from time to
time. Except for the ownership of the Series B Preferred Stock and the warrants,
none of the selling shareholders, other than Transamerica Business Credit
Corporation ("Transamerica"), has had any material relationship with us within
the past three years.
The table below lists the selling shareholders and other information
regarding the beneficial ownership of the common stock by each of the selling
shareholders. The second column lists, for each selling shareholder, the number
of shares of common stock (based on its ownership of Series B Preferred Stock
and related warrants) which would have been issuable to the selling shareholders
on May 10, 2000 upon conversion of all Series B Preferred Stock and exercise of
all warrants held by such selling shareholder on that date, without regard to
any limitations on conversions or exercise. Our calculations of the number of
shares of common stock into which the selling shareholders may convert the
Series B Preferred Stock in the second column assumes a conversion price for the
Series B Preferred Stock of $1.54, which represents 93% of the lowest closing
trade price during the three consecutive trading days through and including May
10, 2000. Because conversion of the Series B Preferred Stock is based on a
formula that depends on the market price of our common stock, the numbers listed
in the second column, other than those for Transamerica, may fluctuate from time
to time and the number of shares that will actually be issued may be more or
less than the 18,873,590 shares being offered by this prospectus. The warrants,
other than those for Transamerica, are exercisable at an adjusted price of $1.50
per share, subject to further adjustment as provided in the warrant agreement.
The third column lists, for each selling shareholder other than Transamerica,
each selling shareholder's pro rata portion (based on its ownership of Series B
Preferred Stock) of the 18,873,590 shares of common stock being offered by this
prospectus. The fourth and fifth columns assume the sale of all of the shares
offered by each selling shareholder.
We determined the number of shares of common stock to be offered for
resale by this prospectus by agreement with the selling shareholders and in
order to adequately cover a reasonable increase in the number of shares
required. For purposes of estimating the number of shares of common stock to be
included in this Registration Statement, we included:
o 12,994,902 shares, representing 200% of the number of shares of
common stock issuable upon conversion of the Series B Preferred
Stock (without regard to any limitation on conversion), determined
as if the Series B Preferred Stock were converted in full at the
conversion price of $1.54 as of May 10, 2000; plus
o 1,713,784 shares, representing 200% of the number of shares of
common stock issuable upon exercise of the warrants relating to
the Series B Preferred Stock (without regard to any limitations on
exercise) as of May 10, 2000; plus
o 50,000 shares of common stock representing 200% of the number of
shares of common stock issuable upon exercise of the warrant
issued to Transamerica Business Credit Corporation; plus
o 1,386,666 shares of common stock representing 200% of the number
of shares of common stock issuable upon exercise of the exchanged
warrants issued to certain
15
<PAGE>
holders of the Series B Preferred Stock (without regard to any
limitations in exercise) in connection with the Redemption and
Exchange Agreement as of May 4, 2000; plus
o 1,300,000 shares of common stock representing 200% of the number
of shares of common stock issuable upon exercise of the new
warrants issued to certain holders of the Series B Preferred
Stock (without regard to any limitations on exercise) in
connection with the Redemption and Exchange Agreement as of
May 4, 2000; plus
o 1,428,238 shares of common stock representing 200% of the number
of shares of common stock which may be issuable as dividends upon
the Series B Preferred Stock.
Under the Articles of Amendment of our Articles of Incorporation for
the Series B Preferred Stock and under the terms of the warrants, no selling
shareholder (other than Transamerica) can convert Series B Preferred Stock or
exercise the warrants, respectively, to the extent such conversion or exercise
would cause such selling shareholder's beneficial ownership of our common stock,
excluding for purposes of such determination shares of common stock issuable
upon conversion of shares of Series B Preferred Stock which have not been
converted and upon exercise of warrants which have not been exercised, to exceed
4.99% of the outstanding shares of our common stock. The amounts in the second
column do not reflect this limitation. The selling shareholders may sell all,
some or none of their shares in this offering. See "Plan of Distribution."
<TABLE>
<CAPTION>
COMMON SHARES COMMON SHARES COMMON SHARES
NAME OF SELLING BENEFICIALLY OWNED OFFERED BY THIS OWNED AFTER PERCENTAGE OF
SHAREHOLDER PRIOR TO OFFERING PROSPECTUS OFFERING CLASS
- --------------- ------------------ --------------- ------------- -------------
<S> <C> <C> <C> <C> <C> <C>
HFTP Investment L.L.C.(1) 3,280,054 (5) 3,280,054 0 0%
Fisher Capital Ltd.(2) 2,965,338 (6) 2,965,338 0 0%
Wingate Capital Ltd (2) 1,816,958 (7) 1,816,958 0 0%
Leonardo, L.P(3) 5,978,944 (8) 5,978,944 0 0%
Royal Bank of Canada (4) 4,782,296 (9) 4,782,296 0 0%
Transamerica Business Credit
Corporation 50,000 (10) 50,000 0 0%
</TABLE>
- --------------------
(1) Promethean Investment Group, LLC, a New York limited liability company
("Promethean"), serves as investment advisor to HFTP Investment, L.L.C.
("HFTP") and may be deemed to share beneficial ownership of the shares
beneficially owned by HFTP by reason of shared power to vote and to dispose
of the shares beneficially owned by HFTP. Promethean disclaims beneficial
ownership of the shares beneficially owned by HFTP. Mr. James F. O'Brien,
Jr. indirectly controls Promethean. Mr. O'Brien disclaims beneficial
ownership of the shares beneficially owned by Promethean and HFTP. HFTP is
not a registered broker-dealer. HFPT, however, is under common control
with, and therefore an affiliate of, a registered broker-dealer.
(2) Citadel Limited Partnership is the trading manager of each of Fisher
Capital Ltd. and Wingate Capital Ltd. (collectively, the "Citadel
Entities") and consequently has voting control and investment discretion
over securities held by the Citadel Entities. Kenneth C. Griffin indirectly
controls Citadel Limited Partnership. The ownership information for each of
the Citadel Entities does not include ownership information for the other
Citadel Entities. Citadel Limited Partnership, Kenneth C. Griffin and each
of the Citadel Entities disclaims ownership of the shares held by the other
Citadel Entities. Neither Fisher nor Wingate is a
16
<PAGE>
registered broker-dealer. Each of Fisher and Wingate, however, is under
common control with, and therefore an affiliate of, a registered
broker-dealer.
(3) Angelo, Gordon & Co., L.P. ("Angelo Gordon") is a general partner of AG
Super Fund International Partners, L.P., Leonardo, L.P. and Raphael, L.P.,
and is the investment advisor of GAM Arbitrage Investment, Inc.
(collectively, the "Angelo Gordon Entities") and consequently has voting
control and investment discretion over securities held by the Angelo Gordon
Entities. The ownership information for each of the Angelo Gordon Entities
does not include the ownership information for the other Angelo Gordon
Entities. Angelo Gordon and each of the Angelo Gordon Entities disclaim
beneficial ownership of the shares held by the other Angelo Gordon
Entities. John M. Angelo, the Chief Executive Officer of Angelo Gordon, and
Michael R. Gordon, the Chief Operating Officer of Angelo Gordon, are the
sole general partners of A.G. Partners, L.P., the sole general partner of
Angelo Gordon. As a result, Mr. Angelo and Mr. Gordon may be considered
beneficial owners of any shares deemed to be beneficially owned by Angelo
Gordon. Angelo Gordon is not a registered broker-dealer. Angelo Gordon,
however, is under common control with, and therefore an affiliate of, a
registered broker-dealer.
(4) Royal Bank of Canada is not a registered broker-dealer. Royal Bank of
Canada, however, controls and is therefore an affiliate of two registered
broker-dealers.
(5) Includes 903,993 shares held of record and up to 402,597 shares of common
stock issuable as of May 10, 2000, upon conversion of the Series B
Preferred Shares at an assumed conversion price of $1.54, up to 1,713,784
shares of common stock issuable upon the exercise of the warrant issued in
connection therewith held of record by HFTP Investment L.L.C. and up to
259,680 shares of common stock issuable as dividends upon the Series B
Preferred Stock.
(6) Includes up to 2,229,870 shares of common stock issuable as of May 10,
2000, upon conversion of the Series B Preferred Shares at an assumed
conversion price of $1.54, up to 512,534 shares of common stock
issuable upon exercise of the warrant issued in connection therewith held
of record by Fisher Capital and up to 222,934 shares of common stock
issuable as dividends upon the Series B Preferred Stock.
(7) Includes up to 1,366,234 shares of common stock issuable as of May 10,
2000, upon conversion of the Series B Preferred Shares at an assumed
conversion price of $1.54, up to 314,132 shares of common stock
issuable upon exercise of the warrant issued in connection therewith held
of record by Wingate Capital and up to 136,592 shares of common stock
issuable as dividends upon the Series B Preferred Stock.
(8) Includes up to 4,496,104 shares of common stock issuable as of May 10,
2000, upon conversion of the Series B Preferred Shares at an assumed
conversion price of $1.54, up to 1,033,334 shares of common stock
issuable upon exercise of the warrant issued in connection therewith held
of record by Leonardo L.P. and up to 449,506 shares of common stock
issuable as dividends upon the Series B Preferred Stock.
(9) Includes up to 3,596,104 shares of common stock issuable as of May 10,
2000, upon conversion of the Series B Preferred Shares at an assumed
conversion price of $1.54, up to 826,666 shares of common stock
issuable upon exercise of the warrant issued in connection therewith held
of record by Royal Bank of Canada and up to 359,526 shares of common stock
issuable as dividends upon the Series B Preferred Stock.
(10) Represents 200% of the number of shares of common stock issuable upon
exercise of the warrant issued in connection with obtaining the consent of
Transamerica Business Credit Corporation to the sale of the Series B
Preferred Shares.
17
<PAGE>
DESCRIPTION OF SECURITIES
The authorized capital stock of ProxyMed consists of 50,000,000 shares
of common stock, par value $.001 per share, and 2,000,000 shares of preferred
stock, par value $.01 per share. At May 10, 2000, 19,734,429 shares of common
stock were issued and outstanding, and 9,310 shares of preferred stock were
issued and outstanding.
Of the 19,734,429 shares of common stock outstanding on May 10, 2000,
this amount does not include the 4,339,536 shares of common stock issuable upon
exercise of currently outstanding warrants, and 2,460,670 shares of common stock
reserved for issuance upon exercise of currently outstanding stock options.
The descriptions below of the terms of the common stock, Series B
Preferred Stock and the related warrants are summaries of the material terms
only and do not purport to be complete. Such descriptions are subject to and
qualified by the actual agreements relating to the Series B Preferred Stock,
such warrants, our amended Articles of Incorporation and By-laws, all of which
have been filed with the SEC and are incorporated into this prospectus by
reference, and by applicable law.
COMMON STOCK
The issued and outstanding shares of common stock are, and the shares
being offered by this prospectus will be, validly issued, fully paid and
non-assessable. The holders of outstanding shares of common stock are entitled
to receive dividends out of assets legally available for them at such times and
in such amounts as the Board of Directors may from time to time determine.
ProxyMed has not paid any dividends and does not expect to pay cash dividends on
its common stock in the foreseeable future.
All shares of common stock have equal voting rights and, when validly
issued and outstanding, have one vote per share in all matters to be voted upon
by the shareholders. Cumulative voting in the election of directors is not
allowed, which means that the holders of more than 50% of the outstanding shares
can elect all the directors if they choose to do so and, in such event, the
holders of the remaining shares will not be able to elect any directors.
The shares have no pre-emptive, subscription, conversion or redemption
rights. Upon liquidation, dissolution or winding-up of ProxyMed, the holders of
common stock are entitled to receive pro rata the assets of ProxyMed which are
legally available for distribution to shareholders.
PREFERRED STOCK
In addition to the Series B Convertible Preferred Stock, the Board of
Directors of ProxyMed has the authority to issue 1,985,000 additional shares of
preferred stock in one or more series and to fix the designation, relative
powers, preferences and rights and qualifications, limitations or restrictions
of all shares of each such series, including dividend rates, conversion rights,
voting rights, redemption and sinking fund provisions, liquidation preferences
and the number of shares constituting each such series, without any further vote
or action by the shareholders.
The issuance of preferred stock could decrease the amount of earnings
and assets available for distribution to holders of common stock or adversely
affect the rights and powers, including voting rights, of the holders of common
stock and could have the effect of delaying, deferring or preventing a change in
control of ProxyMed without further action by the shareholders.
18
<PAGE>
SERIES B PREFERRED STOCK
On December 23, 1999, we issued 15,000 shares of our Series B Preferred
Stock, and warrants to purchase 800,000 shares of our common stock in a private
placement to institutional investors. The net proceeds of the offering, after
expenses, were approximately $14,200,000. J.C. Bradford & Co. served as our
placement agent for this transaction. The shares of Series B Preferred Stock are
non-voting and carry a cumulative dividend at a rate of 6% per annum, payable
quarterly or upon conversion or redemption, which may be paid in cash or common
stock, at our option, subject to certain conditions. The shares of Series B
Preferred Stock mature on December 23, 2001, subject to extension in certain
circumstances, at which time the Series B Preferred Stock will be redeemed or
converted at our option, subject to certain conditions. The conversion price of
the Series B Preferred Stock at maturity is 95% of the average of the closing
trade price on the Nasdaq National Market of the common stock for the 30
consecutive trading days immediately preceding December 23, 2001.
In connection with the sale of the Series B Preferred Stock, we issued
warrants (the "Old Warrants") to purchase up to 800,000 shares of common stock,
subject to adjustment in certain events. The original exercise price of the Old
Warrants was $12.05 per share, subject to adjustment in certain events. The Old
Warrants expire on December 23, 2002. In addition, in order to obtain the
consent of Transamerica Business Credit Corporation to the sale of the Series B
Preferred Stock, a warrant to purchase 25,000 shares of common stock at an
original exercise price of $11.62 per share was issued to Transamerica (the
"Transamerica Warrant") on substantially the same terms as the Old Warrants. If
the Old Warrants which have not been exchanged for Exchanged Warrants (as
defined below) and the Transamerica Warrant were exercised for cash to purchase
881,892 shares of common stock (after giving effect to dilution adjustment
provisions contained therein), we would receive proceeds of $1,575,837. The
exercise price and number of shares of common stock which may be purchased upon
exercise of such warrants continue to be subject to further adjustment upon the
occurrence of certain dilution events including, without limitation, certain
issuances of common stock, stock options or convertible securities or certain
corporate transactions such as stock splits, mergers or asset sales.
REDEMPTION AND EXCHANGE AGREEMENT
The Series B Preferred Stock converts into common stock at a floating
rate based on the market price of the common stock. The lower the price of the
common stock at the time the holder converts, the greater the number of shares
of common stock the holder will receive. The terms of the Series B Preferred
Stock provide that the holders cannot exercise their rights to convert the
Series B Preferred Stock prior to December 23, 2000, unless certain triggering
events occur. One such triggering event occurs if the closing price of the
common stock is below $4.21 for a period of ten consecutive trading days. As of
May 1, 2000, the closing price of the common stock had been below $4.21 for 10
trading days, thus causing the restriction on conversions to cease to be in
effect.
In order to attempt to prevent the conversion of all of the shares of
Series B Preferred Stock and the resulting significant dilution to the holders
of common stock, we engaged in negotiations with the holders of the Series B
Preferred Stock to restructure certain terms of the Series B Preferred Stock.
Effective May 4, 2000, we entered into a Redemption and Exchange Agreement (the
"Redemption Agreement") with holders of 13,000 shares of the Series B Preferred
Stock. Under the terms of the Redemption Agreement, we have redeemed 4,000
shares of the Series B Preferred Stock, and are required to redeem an additional
2,500 shares of the Series B Preferred Stock on each of June 19, 2000, August 1,
2000, and August 31, 2000, and an additional 1,500 shares of the Series B
Preferred Stock on September 29, 2000. The Redemption Agreement provides that
the redemption of the Series B Preferred Stock will be made at 116.5% of the
Conversion Amount (as defined in the Articles of Amendment to our Articles of
Incorporation creating the Series B Preferred Stock) of such
19
<PAGE>
Series B Preferred Stock on the date of such redemption. The Redemption
Agreement also provides for the exchange of 693,333 of the Old Warrants issued
to the holders of the Series B Preferred Stock subject to the Redemption
Agreement for warrants (the "Exchanged Warrants") with an exercise price of
$1.50 per share. In addition, such holders have received, in the aggregate,
650,000 additional warrants (the "New Warrants") at an exercise price of $1.50
per share. The Exchanged Warrants expire on December 23, 2002 and the New
Warrants expire on May 5, 2003. The exercise price and number of shares of
common stock which may be purchased upon exercise of the Exchanged Warrants and
the New Warrants are subject to adjustment upon the occurrence of certain
dilution events which occur 183 days after the date of issuance of such warrants
including, without limitation, certain issuances of common stock, stock options
or convertible securities or certain corporate transactions such as stock
splits, mergers or asset sales. Subject to certain restrictions, the holders of
the Exchanged Warrants and the New Warrants have agreed not to exercise such
warrants for a period of 180 days following their date of issuance. The
redemption of the Series B Preferred Stock in accordance with the Redemption
Agreement are subject to certain closing conditions on each date of redemption.
So long as we remain in compliance with the terms of the Redemption Agreement,
such holders are prohibited from converting their shares of Series B Preferred
Stock into shares of common stock. In addition, as a result of this
restructuring of the Series B Preferred Stock, we expect to incur a substantial
charge in the second quarter of 2000.
Under the terms of the Redemption Agreement, we have agreed to pay the
holders of Series B Preferred Stock subject to such agreement the aggregate
amount of $4,333,333 if there is a change of control of ProxyMed on or before
December 23, 2002.
We have not entered into an agreement to redeem the shares of Series B
Preferred Stock held by the holder of 2,000 shares of the Series B Preferred
Stock. As of May 10, 2000, this holder has converted 1,690 shares of the Series
B Preferred Stock into an aggregate of 1,401,516 shares of common stock and 310
shares of Series B Preferred Stock continue to be held by such holder.
REQUIREMENT OF SHAREHOLDER APPROVAL; POSSIBLE DELISTING FROM NASDAQ
In accordance with Rule 4460 of the Nasdaq Stock Market Marketplace
Rules, which generally requires shareholder approval of transactions that would
result in the issuance of securities representing 20% or more of an issuer's
outstanding listed securities, we are not obligated to issue shares of common
stock upon conversion or the payment of dividends on the Series B Preferred
Stock in excess of 3,663,730 shares, representing 19.9% of our outstanding
shares of common stock on December 23, 1999, the date of issuance of the Series
B Preferred Stock.
The terms of the Series B Preferred Stock provide that we must obtain
shareholder approval of the issuance of (i) the Series B Preferred Stock, (ii)
the Old Warrants, (iii) common stock issuable upon conversion or exercise
thereof, and (iv) common stock as dividends thereon, by the earlier to occur of
our next annual meeting of shareholders or within 60 days after the date that
the number of shares of common stock then issuable upon conversion of the Series
B Preferred Stock equals or exceeds 2,747,461 shares (15% of the number of
shares of common stock outstanding on the date of issuance of the Series B
Preferred Stock for any three of five consecutive days). On April 13, 2000, we
received a notice from counsel to the holders of the Series B Preferred Stock,
pursuant to Section 4(g) of the Securities Purchase Agreement between the buyers
of the Series B Preferred Stock and ProxyMed dated as of December 23, 1999 (the
"Securities Purchase Agreement"), that for the three days ending on and
including April 12, 2000, the number of shares of common stock issuable upon
conversion of all the outstanding shares of Series B Preferred Stock, based upon
the Conversion Price (as defined in the Articles of Amendment) on the applicable
date (without regard to any limitation upon the conversion of the shares of
Series B Preferred Stock) equaled or exceeded 2,747,461 shares, requiring us to
hold a shareholders meeting on or before June 11, 2000. We will
20
<PAGE>
not hold a shareholders meeting, and consequently will not obtain the required
shareholder approval, on or before June 11, 2000.
As a result of not obtaining the required Shareholder Approval of the
Series B Preferred Stock on or prior to June 11, 2000, if we receive a notice
from a holder of Series B Preferred Stock which would require us to convert such
holder's Series B Preferred Stock into a number of shares of common stock which,
when added to all previous shares of common stock issued pursuant to the
conversion of Series B Preferred Stock, would equal or exceed 20% of the number
of shares of common stock outstanding at that time, then we will be required to
either redeem all of the Series B Preferred Stock submitted for redemption or
voluntarily delist our shares from Nasdaq within five business days after the
notice of conversion referred to above. In addition, failure to obtain such
shareholder approval by June 11, 2000, or delisting of the common stock from
Nasdaq, would constitute a "Liquidity Default". See "Effects of Certain Breaches
or Default" under the "Description of Securities." We may not have sufficient
available cash to redeem the Series B Preferred Stock at that time, and thus may
be forced to pursue the option of delisting. In that event, trading in the
common stock would likely decrease substantially, and the price of the common
stock may decline. If we fail to obtain such shareholder approval, there is no
limit on the number of shares of common stock that could be issued upon
conversion of, or the payment of dividends in lieu of cash on, the Series B
Preferred Stock. Notwithstanding the failure to hold a shareholders meeting on
or before June 11, 2000, pursuant to the Redemption Agreement, holders of 13,000
shares of the Series B Preferred Stock have agreed that they will not convert
any of their 9,000 remaining shares of Series B Preferred Stock into common
stock as a result of such failure to hold a meeting if we received such
shareholder approval on or before July 17, 2000, and the remaining holder of
Series B Preferred Stock owns only 310 shares of Series B Preferred Stock as of
May 10, 2000.
REDEMPTION; CONVERSION
Pursuant to the Securities Purchase Agreement, on or prior to June 23,
2000, we are required to either redeem or convert 4,500 shares of Series B
Preferred Stock. Such redemption would be at a price of 107% of the "Conversion
Amount," which is defined for each share of Series B Preferred Stock as the sum
of the amount originally paid for a share of Series B Preferred Stock ($1,000),
plus any unpaid default interest and any unpaid dividends to the date of
determination. A conversion would be at the applicable conversion rate which is
the number of shares of common stock equal to the Conversion Amount defined in
the previous sentence divided by 93% of the lowest closing sale price of the
common stock on the three consecutive trading days ending on and including the
date of determination (the "Conversion Rate"). On or prior to September 22,
2000, we are required to either redeem or force the conversion of an additional
4,500 shares of Series B Preferred Stock at the redemption and conversion prices
described above in this paragraph.
Notwithstanding the terms of the Securities Purchase Agreement
described in the preceding paragraph, pursuant to the Redemption Agreement, we
redeemed 4,000 shares of Series B Preferred Stock as of May 4, 2000 and are
required to redeem an additional 9,000 shares of Series B Preferred Stock on or
before September 29, 2000. The redemption price is 116.5% of the Conversion
Amount.
POSSIBLE EFFECTS ON THE MARKET PRICE OF COMMON STOCK
Because the Series B Preferred Stock converts into common stock at a
floating rate based on the market price of common stock (PROVIDED, that the
conversion price may not exceed $21.26), the lower the price of common stock at
the time the holder converts, the greater the number of shares of common stock
the holder will receive. To the extent the Series B Preferred Stock is converted
or dividends on the Series B Preferred Stock are paid in shares of common stock
rather than cash, a significant amount of common stock may be sold into the
market, which could decrease the price of common stock due to the additional
supply of shares relative to demand in the market. In that case,
21
<PAGE>
we could be required to issue an increasingly greater number of shares of common
stock upon future conversions of Series B Preferred Stock, sales of which could
further depress the market price of common stock. If the sale of a large number
of shares of common stock upon conversion of, or the payment of dividends in
shares of common stock in lieu of cash on, the Series B Preferred Stock results
in a decline in the price of common stock, this event could encourage short
sales of common stock. Short sales could place further downward pressure on the
market price of common stock.
The conversion of, and the payment of dividends in shares of common
stock in lieu of cash on, the Series B Preferred Stock may result in substantial
dilution to the interests of other holders of common stock. Even though no
holder of Series B Preferred Stock may convert our Series B Preferred Stock into
more than 4.99% of our then outstanding common stock (excluding for purposes of
such determination shares of common stock issuable upon conversion of shares of
Series B Preferred Stock which have not been converted and upon exercise of
warrants which have not been exercised), this restriction does not prevent a
holder of Series B Preferred Stock from selling a substantial number of shares
in the market. By periodically selling shares into the market, an individual
holder could eventually sell more than 4.99% of our outstanding common stock
while never holding more than 4.99% at any specific time.
In addition, the exercise price and number of shares of common stock
which may be purchased upon exercise of the Warrants are subject to adjustment
upon certain issuances by us of common stock, stock options, warrants or
convertible securities. If shares of convertible preferred stock are issued in
an equity financing transaction by us with a conversion price below the exercise
price of the Warrants, or warrants are issued with an exercise price below the
exercise price of the Warrants, the number of shares of common stock which may
be purchased upon exercise of the Warrants may be substantially increased. A
substantial increase in the number of shares of common stock issuable upon
exercise of the Warrants will have the effect of significantly diluting or
adversely affecting the holdings or the rights of the holders of common stock.
NUMBER OF SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION OF SERIES B PREFERRED
The following table sets forth the number of shares of common stock
that we would be required to issue upon conversion of all 9,310 shares of Series
B Preferred Stock currently outstanding at the applicable conversion price of
$1.54 per share of common stock as of May 10, 2000 (93% of the market price),
and the resulting percentage of our total shares of common stock outstanding
after such conversion. The table also sets forth the results of such
calculations assuming (1) increases of 25%, 50% and 75% in the applicable
conversion price; (2) decreases of 25%, 50% and 75% in the applicable conversion
price; and (3) the fixed conversion price of $21.26 which is the maximum
permitted conversion price. The table includes the 9,000 shares of Series B
Preferred Stock that we have agreed to redeem pursuant to the Redemption
Agreement. The table does not reflect the number of shares that we would be
required to issue if a Liquidity Default occurs and the conversion rate is
reduced to 68%. The result of such event would be to materially increase the
number of shares of common stock outstanding. See "Effects of Certain Breaches
or Defaults."
22
<PAGE>
<TABLE>
<CAPTION>
NO. OF SHARES
ASSUMED CONVERSION COMMON STOCK PERCENTAGE OF
PRICE PER SHARE ISSUABLE UPON OUTSTANDING COMMON
OF COMMON STOCK CONVERSION(1) STOCK AFTER CON
VERSION(1)
- ------------------------------- -------------------------- ----------------------------------
<S> <C> <C> <C> <C>
$21.26 $21.26 437,912 2.3%
$1.93 25% 4,835,236 20.9%
$2.31 50% 4,029,364 18.0%
$2.70 75% 3,453,740 15.9%
$1.54 6,044,046 24.8%
$1.16 -25% 8,058,727 30.6%
$0.77 -50% 12,088,091 39.8%
$0.39 -75% 24,176,182 56.9%
</TABLE>
- ------------------------
(1) The number of shares of common stock issuable upon conversion and the
percentage of outstanding common stock after such conversion set forth
above do not take into account any shares of common stock that may be
issuable as dividends on the Series B Preferred Stock, or upon exercise
of the Old Warrants which have not been exchanged for Exchanged
Warrants, the Transamerica Warrant, the Exchanged Warrants and the New
Warrants (collectively, the "Warrants").
If the 9,310 Series B Preferred Stock currently outstanding had been
converted in full and all of the Warrants had been fully exercised as of May 10,
2000, we would have been required to issue an additional 15,195,127 shares of
common stock, equivalent to 43.5% of the 34,929,556 shares of common stock which
would then be outstanding.
POSSIBLE PAYMENT OF DIVIDENDS IN COMMON STOCK
At our option, subject to certain conditions, the quarterly dividend
may be paid in cash or common stock, subject to satisfaction of certain
conditions. If we choose to pay dividends in common stock, the number of shares
to be issued in payment of the dividend on the Series B Preferred Stock will be
equal to (1) the sum of any unpaid default interest and any unpaid dividends to
the date of determination divided by (2) 93% of the lowest closing sale price of
the common stock on the three consecutive trading days ending on and including
the date which is two trading days prior to the date that the dividend is
payable. On March 31, 2000, we issued 29,278 shares of common stock as dividends
on the Series B Preferred Stock.
EFFECTS OF CERTAIN BREACHES OR DEFAULTS
If certain defaults or breaches of the Articles of Amendment, the Old
Warrants, the Securities Purchase Agreement or the related registration rights
agreement occur (each defined as a "Liquidity Default"), the holders of the
Series B Preferred Stock have the right to require us to make certain additional
cash payments to the holders of the Series B Preferred Stock or, depending upon
the nature of the Liquidity Default, adjust downward the maximum conversion
price. If we default under certain provisions of the Articles of Amendment,
including a failure to timely make a payment required by a Liquidity Default (a
"Triggering Event"), then, except in the case of the Triggering Event involving
failure to obtain the shareholder approval on or before June 11, 2000 (which is
described above in connection with the possible delisting of the common stock
from Nasdaq), we would be required to redeem the Series B Preferred Stock at a
price equal to the greater of (1) 125% of the liquidation preference described
in the following paragraph; or (2) the Conversion Rate in effect when a holder
of Series B Preferred Stock demands redemption multiplied by the closing sale
23
<PAGE>
price of the common stock on the trading day immediately preceding the date of
such Triggering Event.
If certain defaults or breaches of the Redemption Agreement, the
Exchanged Warrants, the New Warrants or the related registration rights
agreement occur, or if certain Triggering Events or Liquidity Events occur under
the Stock Purchase Agreement, the restrictions on conversion of Series B
Preferred Stock into common stock set forth in the Redemption Agreement will no
longer be applicable.
LIQUIDATION RIGHTS
In the event of the liquidation of ProxyMed, the holders of the Series
B Preferred Stock will be entitled to a liquidation preference before any
amounts are paid to the holders of common stock. The liquidation preference is
equal to the amount originally paid for the Series B Preferred Stock ($1,000 per
share) plus accrued and unpaid dividends (and any unpaid default interest) on
any outstanding Series B Preferred Stock through the date of determination.
VOTING RIGHTS
Other than as required by law, the holders of the Series B Preferred
Stock have no voting rights except that the consent of holders of at least
two-thirds of the outstanding Series B Preferred Stock will be required to (1)
effect any change in our Articles of Incorporation that would change any of the
rights of the Series B Preferred Stock; or (2) issue any Series B Preferred
Stock other than pursuant to the Securities Purchase Agreement.
FOR MORE INFORMATION
Complete copies of the Articles of Amendment, the form of the Old
Warrants and the Securities Purchase Agreement are contained in our Current
Report on Form 8-K filed with the Securities and Exchange Commission on December
28, 1999 and are incorporated herein by reference. Complete copies of the
Redemption Agreement, the Exchanged Warrants and the New Warrants are contained
in our Current Report on Form 8-K filed with the Securities and Exchange
Commission on May 8, 2000 and are incorporated herein by reference. The
descriptions of these documents are summaries of the material terms and
conditions only and are qualified in their entirety by reference to the complete
documents which are publicly available from the Securities and Exchange
Commission.
In connection with our issuance of the Series B Preferred Stock, the
Old Warrants and the Transamerica Warrant, we filed a registration statement on
Form S-3 with the Securities and
24
<PAGE>
Exchange Commission (File No. 333-95883) which was declared effective on
February 11, 2000. That registration statement covers the resale of the common
stock from time to time on the Nasdaq National Market or in privately negotiated
transactions of the common stock which is issuable upon conversion of the Series
B Preferred Stock, in lieu of cash dividends on the Series B Preferred Stock and
upon exercise of the Old Warrants and the Transamerica Warrant.
CERTAIN ANTI-TAKEOVER PROVISIONS
Under ProxyMed's Articles of Incorporation, there are approximately
25,000,000 unissued, unreserved shares of common stock and 1,990,690 shares of
preferred stock available for future issuance without shareholder approval. The
existence of authorized but unissued capital stock could have the effect of
making more difficult or discouraging an acquisition of ProxyMed deemed
undesirable by our Board of Directors.
The State of Florida has enacted certain legislation that may deter or
frustrate takeovers of Florida corporations. The Florida Control Share Act
generally provides that shares acquired in excess of certain specified
thresholds will not possess any voting rights unless such voting rights are
approved by a majority vote of the corporation's disinterested shareholders. The
Florida Affiliated Transactions Act generally requires supermajority approval by
disinterested directors or shareholders of certain specified transactions
between a public corporation and holders of more than 10% of the outstanding
voting shares of the corporation (or their affiliates).
NASDAQ NATIONAL MARKET
ProxyMed's common stock is, and the shares being offered by this
prospectus will be, traded in the Nasdaq National Market unless our common stock
is delisted from Nasdaq.
TRANSFER AGENT AND REGISTRAR
The transfer agent and registrar for our common stock is North American
Transfer Company, Freeport, New York.
25
<PAGE>
PLAN OF DISTRIBUTION
The selling shareholders (or, subject to applicable law, their pledges,
donees, distributees, transferees or successors in interest) are offering shares
of our common stock, which are issuable to them upon conversion of the Series B
Preferred Stock, in lieu of cash dividends on the Series B Preferred Stock, and
upon exercise of warrants that they acquired from us in a private placement
transaction. This prospectus covers the selling shareholders' resale of up to
18,873,590 shares of our common stock that we may issue to them upon conversion
of the Series B Preferred Stock, as payments of dividends thereon and upon
exercise of the related warrants, as well as any additional shares that may
become issuable upon conversion of the Series B Preferred Stock or exercise of
the warrants because of stock splits, stock dividends and other specified
transactions.
In connection with our issuance to the selling shareholders of the
Series B Preferred Stock and the related warrants, we filed a registration
statement on Form S-3 with the SEC which was declared effective by the SEC on
February 11, 2000. We subsequently filed this registration statement, also on
Form S-3. That earlier registration statement and this one cover the resale of
the common stock referred to above from time to time on the Nasdaq National
Market or in privately-negotiated transactions. This prospectus forms a part of
the second registration statement. We have also agreed to prepare and file any
amendments and supplements to these registration statements as may be necessary
to keep them effective until this prospectus is no longer required for the
selling shareholders to sell their shares of common stock, and to indemnify and
hold the selling shareholders harmless against certain liabilities under the
Securities Act that could arise in connection with the selling shareholders'
sale of their shares. We have agreed to pay all reasonable fees and expenses
incident to the filing of these registration statements, but the selling
shareholders will pay any brokerage commissions, discounts or other expenses
relating to the sale of their common stock.
The selling shareholders may sell the shares of common stock described
in this prospectus directly or through underwriters, broker-dealers or agents.
The selling shareholders may also transfer, devise or give their shares by other
means not described in this prospectus. As a result, pledges, donees,
transferees or other successors in interest that receive such shares as a gift,
partnership distribution or other non-sale related transfer may offer shares of
common stock under this prospectus. In addition, if any shares covered by this
prospectus qualify for sale pursuant to Rule 144 under the Securities Act, the
selling shareholders may sell such shares under Rule 144 rather than pursuant to
this prospectus.
The selling shareholders may sell shares of common stock from time to
time in one or more transactions:
o at fixed prices that may be changed,
o at market prices prevailing at the time of sale, or
o at prices related to such prevailing market prices or at
negotiated prices.
The selling shareholders may offer their shares of common stock in one
or more of the following transactions:
o on any national securities exchange or quotation service on which
the common stock may be listed or quoted at the time of sale,
including the Nasdaq National Market,
o in the over-the-counter market,
26
<PAGE>
o in privately-negotiated transactions,
o through options,
o by pledge to secure debts and other obligations,
o by a combination of the above methods of sale, or
o to cover short sales made pursuant to this prospectus.
In effecting sales, broker or dealers engaged by the selling
shareholders or affiliated with them may arrange for other brokers or dealers to
participate in the resales. The selling shareholders may enter into hedging
transactions with broker-dealers, and in connection with those transactions,
broker-dealers may engage in short sales of the shares. The selling shareholders
also may sell shares short and deliver the shares to close out such short
positions. The selling shareholders also may enter into option or other
transactions with broker-dealers that require the delivery to the broker-dealer
of the shares, which the broker-dealer may resell pursuant to this prospectus.
The selling shareholders also may pledge the shares to a broker or dealer, and
upon a default, the broker or dealer may effect sales of the pledged shares
pursuant to this prospectus.
The SEC may deem the selling shareholders and any underwriters,
broker-dealers or agents that participate in the distribution of the shares of
common stock to be "underwriters" within the meaning of the Securities Act. The
SEC may deem any profits on the resale of the shares of common stock and any
compensation received by any underwriter, broker-dealer or agent to be
underwriting discounts and commissions under the Securities Act. Each selling
shareholder which purchased Series B Preferred Stock has advised us that it has
purchased the Series B Preferred Stock and related warrants in the ordinary
course of our business, and at the time the selling shareholder purchased the
Series B Preferred Stock and related warrants, it was not a party to any
agreement or other understanding to distribute the securities, directly or
indirectly.
Under the Exchange Act, any person engaged in the distribution of the
shares of common stock may not simultaneously engage in market-making activities
with respect to the common stock for five business days prior to the start of
the distribution. In addition, each selling shareholder and any other person
participating in a distribution will be subject to the Exchange Act, which may
limit the timing of purchases and sales of common stock by the selling
shareholder or any other person.
LEGAL OPINION
The validity of the common stock offered hereby will be passed on for
us by Holland & Knight LLP, 701 Brickell Avenue, Suite 3000, Miami, Florida
33131.
EXPERTS
The consolidated balance sheets of ProxyMed as of December 31, 1999 and
1998, and the related consolidated statements of operations, stockholders'
equity and cash flows of ProxyMed for each of the three years in the period
ended December 31, 1999, that are incorporated by reference in this prospectus
have been incorporated by reference in reliance on the report of
PricewaterhouseCoopers LLP, independent accountants, given on that firm's
authority as experts in accounting and auditing.
27
<PAGE>
PART II
INFORMATION NOT REQUIRED IN PROSPECTUS
ITEM 14. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION.
The following table sets forth the costs and expenses in connection
with the sale and distribution of the securities being registered, other than
underwriting discounts and commissions. All of the amounts shown are estimates
except the Securities and Exchange Commission registration fee.
TO BE PAID
BY THE
REGISTRANT
----------
SEC registration fee............................. $ 8,253
Accounting fees and expenses..................... 5,000
Legal fees and expenses.......................... 15,000
Miscellaneous expenses........................... 1,747
===================
Total..................................... $ 30,000
ITEM 15. INDEMNIFICATION OF DIRECTORS AND OFFICERS.
Section 607.0850 of the Florida Business Corporation Act empowers a
Florida corporation to indemnify any person who was or is a party to any
proceeding (other than an action by or in the right of such corporation) by
reason of the fact that such person is or was a director, officer, employee, or
agent of such corporation, or is or was serving at the request of such
corporation as a director, officer, employee or agent of another corporation,
partnership, joint venture, trust or other enterprise, against liability
incurred in connection with such proceeding, including any appeal thereof, if
such person acted in good faith and in a manner such person reasonably believed
to be in or not opposed to the best interests of the corporation, and, with
respect to any criminal action or proceeding, such person had no reasonable
cause to believe his conduct was unlawful. A Florida corporation may indemnify
such person against expenses including amounts paid in settlement (not
exceeding, in the judgment of the board of directors, the estimated expense of
litigating the proceeding to conclusion) actually and reasonably incurred by
such person in connection with actions brought by or in the right of the
corporation to procure a judgment its favor under the same conditions set forth
above, if such person acted in good faith and in a manner such person believed
to be in, or not opposed to, the best interests of the corporation, except that
no indemnification is permitted in respect of any claim, issue or matter as to
which such person shall have been adjudged to be liable to the corporation
unless and to the extent the court in which such action or suit was brought or
other court of competent jurisdiction shall determine upon application that, in
view of all the circumstances of the case, such person is fairly and reasonably
entitled to indemnity for such expenses as the court shall deem proper.
To the extent such person has been successful on the merits or
otherwise in defense of any action referred to above, or in defense of any
claim, issue or matter therein, the corporation must indemnify such person
against expenses, including counsel (including those for appeal) fees, actually
and reasonably incurred by such person in connection therewith. The
indemnification and advancement of expenses provided for in, or granted pursuant
to, Section 607.0850 is not exclusive of any other rights to which those seeking
indemnification or advancement of expenses may be entitled under the articles of
incorporation of ProxyMed or any by-law, agreement, vote of shareholders or
disinterested directors, or otherwise. Section 607.0850 also provides that a
corporation may
II-1
<PAGE>
maintain insurance against liabilities for which indemnification is not
expressly provided by the statute.
Article VII of ProxyMed's Restated Articles of Incorporation and
Article VII of ProxyMed's Bylaws provide for indemnification of the directors,
officers, employees and agents of ProxyMed (including the advancement of
expenses) to the fullest extent permitted by Florida law. In addition, ProxyMed
has contractually agreed to indemnify its directors and officers to the fullest
extent permitted under Florida law.
ProxyMed's employment agreements with its principal executive officers
limit their personal liability for monetary damages for breach of their
fiduciary duties as officers and directors, except for liability that cannot be
eliminated under the Florida Business Corporation Act.
ITEM 16. EXHIBITS
The following exhibits are filed with this Registration Statement:
EXHIBIT NO. DESCRIPTION OF DOCUMENTS
2.1 Stock Purchase Agreement, dated April 24, 1998, between
ProxyMed, Inc. and WPJ, Inc. (1)
2.2 Merger Agreement, dated as of December 30, 1998, between
ProxyMed, Inc., ProxyMed Acquisition Corp. and Key
Communications Service, Inc. (2)
3.3 Articles of Amendment to Articles of Incorporation of
ProxyMed, Inc. (3)
4.1 Form of Warrant to Purchase Common Stock of ProxyMed, Inc.,
dated December 23, 1999, issued to certain investors. (3)
4.2 Registration Rights Agreement, dated as of December 23, 1999,
by and among ProxyMed, Inc. and the investors named therein.
(3)
4.3 Form of Exchanged Warrant to Purchase Common Stock of
ProxyMed, Inc., dated May 4, 2000, issued to certain
investors. (4)
4.4 Form of New Warrant to Purchase Common Stock of ProxyMed,
Inc., dated May 4, 2000, issued to certain investors. (4)
4.5 Registration Rights Agreement, dated as of May 4, 2000, by and
among ProxyMed, Inc. and the investors named therein. (4)
5.1 Opinion of Holland & Knight LLP
10.24 Securities Purchase Agreement, dated as of December 23, 1999,
by and among ProxyMed, Inc. and the investors listed on the
Schedule of Buyers attached thereto. (3)
10.27 Redemption and Exchange Agreement, dated as of May 4, 2000, by
and among ProxyMed, Inc. and the investors named therein. (4)
23.1 Consent of Holland & Knight LLP (included in the opinion filed
as Exhibit 5.1).
II-2
<PAGE>
23.2 Consent of PricewaterhouseCoopers LLP.
24.1 Power of Attorney (set forth on signature page of the
Registration Statement).
- --------------------
(1) Incorporated by reference to the exhibits filed with Current Report on Form
8-K dated May 19, 1998.
(2) Incorporated by reference to the exhibits filed with Current Report on Form
8-K dated December 31, 1998.
(3) Incorporated by reference to the exhibits filed with Current Report on Form
8-K dated December 23, 1999.
(4) Incorporated by reference to the exhibits filed with Current Report on Form
8-K dated May 8, 2000.
ITEM 17. UNDERTAKINGS.
(a) The undersigned Registrant hereby undertakes: (1) to file, during
any period in which offers or sales are being made, a post-effective amendment
to this Registration Statement: (i) to include any prospectus required by
Section 10(a)(3) of the Securities Act of 1933; (ii) to reflect in the
prospectus any facts or events arising after the effective date of the
Registration Statement (or the most recent post-effective amendment thereof)
which, individually or in the aggregate, represent a fundamental change in the
information set forth in the Registration Statement; and (iii) to include any
material information with respect to the plan of distribution not previously
disclosed in the Registration Statement or any material change to such
information in the Registration Statement; (2) that, for the purpose of
determining any liability under the Securities Act of 1933, each such
post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities
at the time shall be deemed to be the initial bona fide offering thereof; and
(3) to remove from registration by means of a post-effective amendment any of
the securities being registered which remain unsold at the termination of the
offering.
(b) The undersigned Registrant hereby undertakes that, for purposes of
determining any liability under the Securities Act of 1933, each filing of the
Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the
Exchange Act of 1934 (and, where applicable, each filing of an employee benefit
plan's annual report pursuant to Section 15(d) of the Exchange Act) that is
incorporated by reference in the Registration Statement shall be deemed to be a
new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial bona
fide offering thereof.
(c) Insofar as indemnification for liabilities arising under the
Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the Registrant pursuant to the foregoing provisions, or otherwise,
the Registrant has been advised that in the opinion of the Securities and
Exchange Commission such indemnification is against public policy as expressed
in the Act and is, therefore, unenforceable. In the event that a claim for
indemnification against such liabilities (other than the payment by the
Registrant of expenses incurred or paid by a director, officer or controlling
person of the Registrant in the successful defense of any action, suit or
proceeding) is asserted by such director, officer or controlling person in
connection with the securities being registered, the Registrant will, unless in
the opinion of its counsel the matter has been settled by controlling precedent,
submit to a court of appropriate jurisdiction the question whether such
indemnification by
II-3
<PAGE>
it is against public policy as expressed in the Act and will be governed by the
final adjudication of such issue.
(d) The undersigned Registrant hereby undertakes that: (i) for the
purposes of determining any liability under the Securities Act, the information
omitted from the form of prospectus filed as part of this Registration Statement
in reliance upon Rule 430A and contained in a form of prospectus filed by the
Registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act
shall be deemed to be part of the registration statement as of the time it was
declared effective; and (ii) for the purposes of determining any liability under
the Securities Act, each post-effective amendment that contains a form of
prospectus shall be deemed to be a new registration statement relating to the
securities offered therein, and the offering of such securities at that time
shall be deemed to be the initial bona fide offering thereof.
II-4
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the
Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form S-3 and has duly caused this Registration
Statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Fort Lauderdale, State of Florida, on May 12, 2000.
PROXYMED, INC.
By: /s/ John B. Okkerse, Jr.
---------------------------
John B. Okkerse, Jr., Ph.D.
Chief Executive Officer
KNOW ALL MEN BY THESE PRESENTS, that each person whose signature
appears below constitutes and appoints Harold S. Blue, Bennett Marks and Frank
M. Puthoff, and each of them, his true and lawful attorney-in-fact and agent,
with full power of substitution, for him and in his name, in any and all
capacities, to sign all amendments (including post-effective amendments) to the
Registration Statement to which this power of attorney is attached, and to file
all those amendments and all exhibits to them and other documents to be filed in
connection with them, including any registration statement pursuant to Rule 462
under Securities Act of 1933, with the Securities and Exchange Commission.
Pursuant to the requirements of the Securities Act of 1933, this
Registration Statement has been signed by the following persons in the
capacities and on the dates indicated.
<TABLE>
<CAPTION>
SIGNATURES TITLE DATE
<S> <C> <C>
/s/ Harold S. Blue Chairman of the Board May 12, 2000
- -----------------------------
Harold S. Blue
/s/ John B. Okkerse, Jr. Chief Executive Officer and Director May 12, 2000
- ----------------------------- (principal executive officer)
John B. Okkerse, Jr., Ph.D.
/s/ Bennett Marks Executive Vice President, Chief Financial May 12, 2000
- ----------------------------- Officer and Director (principal financial
Bennett Marks and accounting officer)
/s/ Peter A.A. Saunders Director May 12, 2000
- -----------------------------
Peter A.A. Saunders
/s/ Keven E. Moley Director May 12, 2000
- -----------------------------
Keven E. Moley
/s/ Bertram Polan Director May 12, 2000
- -----------------------------
Bertram Polan
/s/ Eugene R. Terry Director May 12, 2000
- -----------------------------
Eugene R. Terry
</TABLE>
II-5
<PAGE>
INDEX TO EXHIBITS
EXHIBIT NO. DESCRIPTION OF DOCUMENTS
5.1 Opinion of Holland & Knight LLP.
23.1 Consent of Holland & Knight LLP (included in the opinion filed
as Exhibit 5.1).
23.2 Consent of PricewaterhouseCoopers LLP.
24.1 Power of Attorney (set forth on signature page of the
Registration Statement).
EXHIBIT 5.1
Holland & Knight LLP
701 Brickell Avenue
Suite 3000
Miami, Florida 33131
May __, 2000
ProxyMed, Inc.
2555 Davie Road
Suite 110
Ft. Lauderdale, Florida 33317
Re: ProxyMed, Inc.-- Registration Statement on Form S-3
(File No. 333-______)
Gentlemen:
We refer to the Registration Statement (the "Registration Statement")
on Form S-3 (File No. 333-______), filed by ProxyMed, Inc. (the "Company"), with
the Securities and Exchange Commission, for the purpose of registering under the
Securities Act of 1933 an aggregate of 14,284,547 additional shares (the
"Shares") of the authorized common stock, par value $.01 per share (the "Common
Stock"), of the Company being offered to the public.
In connection with the foregoing registration, we have acted as counsel
for the Company, and have examined originals, or copies certified to our
satisfaction of all such corporate records of the Company, certificates of
public officials and representatives of the Company, and other documents as we
deemed it necessary to require as a basis for the opinion hereafter expressed.
Based on the foregoing, and having regard for legal considerations that
we deem relevant, it is our opinion that the Shares, when issued and delivered
in accordance with the terms of the instruments governing their issuance, will
be duly authorized, legally issued, fully paid and nonassessable.
We hereby consent to the filing of this opinion as Exhibit 5 to the
Registration Statement, and to the reference to this firm under the caption
"Legal Matters" in the Registration Statement. In giving such consent, we do not
thereby admit that we are in the category of persons whose consent is required
under Section 7 of the Securities Act.
Very truly yours,
Holland & Knight
EXHIBIT 23.2
CONSENT OF INDEPENDENT ACCOUNTANTS
We hereby consent to the incorporation by reference in this
Registration Statement on Form S-3 of our report dated February 21, 2000,
relating to the financial statements and financial statement schedules, which
appears in ProxyMed, Inc.'s Annual Report on Form 10-K for the years ended
December 31, 1999 and 1998. We also consent to the references to us under the
heading "Experts" in such Registration Statement.
PricewaterhouseCoopers LLP
Miami, Florida
May 12, 2000
